Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Amgen Drops 10% on a Trial It Didn't Even Run AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.
Novartis, Ionis Tumble On Surprise Flop For Heart Drug Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.
The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.
Why Novartis Just Surged 6%, Eyeing A Breakout Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.
Breakfast News: A Conversation With Ionis CEO Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.
The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.
